Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer

Michl, Marlies; Taverna, F.; Kumbrink, Jörg; Schiergens, Tobias S.; Heinemann, Volker; Engel, Jutta; Kirchner, Thomas; Neumann, Jens (9. December 2020): Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer. In: Virchows Archiv [Forthcoming]

Abstract

Metastatic spread is the most important life-threatening feature of colorectal cancer and is supposed to be mainly driven by alterations in different carcinogenic pathways. The present study compared mutation and expression profiles of distinctive biomarkers in colorectal cancer patients with different clinical metastatic patterns. As for a case-control study, patients were matched according to T category, grading and primary tumour site. Overall, 246 patients with either exclusive lung metastasis (N = 82), exclusive liver metastasis (N = 82) or non-metastatic colorectal cancer (N = 82) were identified. Paraffin-embedded specimens were examined for mutations in the RAS and RAF genes and for the expression of β-catenin and CD133. Clinical endpoints were presence or absence of distant metastasis, formation of metastasis in lungs versus the liver and survival. MAPK pathway mutations in either the KRAS, NRAS or BRAF gene were associated with the development of lung metastasis (63.4%) compared to the control group (47.6%; p = 0.04). MAPK pathway alterations plus high β-catenin expression were associated with metastasis to the lungs but not to the liver (28.0% vs. 13.4%; p = 0.02). High CD133 expression correlated with the development of liver metastasis compared to the control group (30.5% vs. 14.6%; p = 0.02). This data indicates that different patterns of distant spread are associated with specific biomarker alterations and may represent different molecular subtypes of colorectal cancer. However, underlying mechanisms of metastasis formation in different anatomic sites remains unclear. Since knowledge of the anticipated site of distant spread would substantially impact clinical management, further research is needed to identify solid biomarkers for different metastatic patterns.

• Item Type: Journal article
• Form of publication: Publisher's Version
• Keywords: Biomarker; CD133; Lung metastasis; MAPK pathway mutations; Metastatic colorectal cancer; β-catenin
• Faculties: Medicine > Institute for Medical Information Processing, Biometry and Epidemiology
• Subjects: 600 Technology > 610 Medicine and health
• Language: English

References

Qiu M, Hu J, Yang D, Cosgrove DP, Xu R (2015) Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget 6:38658–38666. https://doi.org/10.18632/oncotarget.6130 - DOI - PubMed - PMC Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM (2010) Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 59:1383–1388. https://doi.org/10.1136/gut.2010.211557 - DOI - PubMed Haussmann J, Matuschek C, Bölke E, Orth K, Ghadjar P, Budach W (2019) The role of local treatment in oligometastatic and oligoprogressive cancer. Dtsch Arztebl Int 116(50):849–856. https://doi.org/10.3238/arztebl.2019.0849 - DOI - PubMed - PMC Van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422. https://doi.org/10.1093/annonc/mdw235 - DOI - PubMed Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580. https://doi.org/10.1200/JCO.2007.11.0833 - DOI - PubMed Pfannschmidt J, Dienemann H, Hoffmann H (2007) Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 84:324–338 - DOI Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318. https://doi.org/10.1097/00000658-199909000-00004 - DOI - PubMed - PMC Meimarakis G, Spelsberg F, Angele M, Preissler G, Fertmann J, Crispin A, Reu S, Kalaitzis N, Stemmler M, Giessen C, Heinemann V, Stintzing S, Hatz R, Winter H (2014) Resection of pulmonary metastases from colon and rectal cancer: factors to predict survival differ regarding to the origin of the primary tumor. Ann Surg Oncol 21:2563–2572. https://doi.org/10.1245/s10434-014-3646-1 - DOI - PubMed Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser V, Al-Batran S-E, Heintges T, Kahl C et al (2017) Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer 79:50–60. https://doi.org/10.1016/j.ejca.2017.03.023 - DOI - PubMed Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a metaanalysis of randomized, controlled trials. Ann Oncol 26:13–21. https://doi.org/10.1093/annonc/mdu378 - DOI - PubMed Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A (2016) Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 27:1746–1753. https://doi.org/10.1093/annonc/mdw261 - DOI - PubMed - PMC Andre T, Shiu K-K, Kim TW et al Pembrolizumab vs chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. J Clin Oncol 38: 2020 (suppl; abstr LBA4). https://doi.org/10.1200/JCO.2020.38.18_suppl.LBA4 Lipsyc MD, Yaeger R (2015) Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol 6:645–649. https://doi.org/10.3978/j.issn.2078-6891.2015.045 - DOI - PubMed - PMC Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang Z-Q, Hoff PM, Vauthey J-N, Vilar E, Maru D, Kopetz S (2015) Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112:424–428. https://doi.org/10.1038/bjc.2014.619 - DOI - PubMed Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M, Drummond KJ, Thomson BNJ, Usatoff V, Evans PM, Pick AW, Knight S, Carne PWG, Berry R, Polglase A, McMurrick P, Zhao Q, Busam D, Strausberg RL, Domingo E, Tomlinson IPM, Midgley R, Kerr D, Sieber OM (2011) KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 17:1122–1130. https://doi.org/10.1158/1078-0432.CCR-10-1720 - DOI - PubMed Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, Kemeny N (2015) RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 121:1195–1203. https://doi.org/10.1002/cncr.29196 - DOI - PubMed Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeño J, Belda-Iniesta C, Barriuso J, Moreno García V, Larrauri J, López R, Casado E, Gonzalez-Barón M, Feliuet J (2009) KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 4:e8199. https://doi.org/10.1371/journal.pone.0008199 - DOI - PubMed - PMC El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S (2015) Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther 16(12):1726–1737. https://doi.org/10.1080/15384047.2015.1113356 - DOI - PubMed - PMC Neumann J, Horst D, Kriegl L, Maatz S, Engel J, Jung A, Kirchner T (2012) A simple immunohistochemical algorithm predicts the risk of distant metastases in right-sided colon cancer. Histopathology 60:416–426. https://doi.org/10.1111/j.1365-2559.2011.04126.x - DOI - PubMed Horst D, Reu S, Kriegl L, Engel J, Kirchner T, Jung A (2009) The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer. Cancer 115:2063–2070. https://doi.org/10.1002/cncr.24254 - DOI - PubMed Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, Jung A (2009) The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 219:427–434. https://doi.org/10.1002/path.2597 - DOI - PubMed Neumann J, Löhrs L, Albertsmeier M, Reu S, Guba M, Kirchner T, Angele M (2015) The stem cell associated biomarker CD133 is associated with distant hematogeneous liver metastases but not with peritoneal carcinomatosis in colorectal cancer. Cancer Investig 33(8):354–360. https://doi.org/10.3109/07357907.2015.1047507 - DOI Michl M, Heinemann V, Jung A, Kirchner T, Neumann J (2015) Expression of stemness associated markers correlates with distant spread to the liver but not to with brain metastases in colorectal cancer. Pathol Res Pract 211(8):601–609. https://doi.org/10.1016/j.prp.2015.05.006 - DOI - PubMed Yamashita S, Chun YS, Kopetz SE, Vauthey JN (2018) Biomarkers in colorectal liver metastases. Br J Surg 105:618–627. https://doi.org/10.1002/bjs.10834 - DOI - PubMed Patel JN, Fong MK, Jagosky M (2019) Colorectal cancer biomarkers in the era of personalized medicine. J Pers Med 9:3. https://doi.org/10.3390/jpm9010003 - DOI - PMC Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, Laurent-Puig P (2019) The evolving biomarker landscape for treatment selection in metastatic colorectal cancer. Drugs 79:1375–1394. https://doi.org/10.1007/s40265-019-01165-2 - DOI - PubMed - PMC Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6:479–507. https://doi.org/10.1146/annurev-pathol-011110-130235 - DOI - PubMed Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, Louvard D, Fodde R, Robine S (2006) APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 131:1096–1109. https://doi.org/10.1053/j.gastro.2006.08.011 - DOI - PubMed Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA (2012) Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res 72:1547–1556. https://doi.org/10.1158/0008-5472.CAN-11-3222 - DOI - PubMed - PMC Horst D, Kriegl L, Engel J, Kirchner T, Jung A (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99:1285–1289. https://doi.org/10.1038/sj.bjc.6604664 - DOI - PubMed - PMC Koehne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13:308–317. https://doi.org/10.1093/annonc/mdf034 - DOI Khattak MA, Martin HL, Beeke C, Price T, Carruthers S, Kim S, Padbury R, Karapetis CS (2012) Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 11:247–254. https://doi.org/10.1016/j.clcc.2012.06.004 - DOI - PubMed